Cell type-associated traits map for the [AdultStomach_B cell (Plasmocyte)][link to cell ontology]. Due to the large number of UKBB panel traits, this figure shows the non-UKBB traits with a CSEA p (chi2) < 1e-04 as default, and users can change it to 1e-03, 1e-05, or 1e-06. For each cell type and trait association pair (shown as an edge in the figure), there may be multiple TAG sets, each defined at a different threshold. The pair with the minimum p-value is shown in the figure, with the p-value showing along each edge. The number of edges in the figure is thus less than (or equal to) the number of entries in the table below.” The association association is listed in the table at bottom, Because each trait might have multiple TAG sets defined at different thresholds, multiple rows for each cell type and trait pair with different "TAG Set Threshold" and " CSEA p (chi2)" (the last two columns).
Table. List of Cell type-associated traits pairs for [AdultStomach_B cell (Plasmocyte)]. If the network above is too complicated. the users could obtain the association information from the table at bottom. Because each trait has multiple TAG sets defined at different thresholds, there may be multiple rows for each cell type and trait pair with different "TAG Set Threshold" and " CSEA p (chi2)" (the last two columns). Users could identify the most significant association by sorting “CSAE p (chi2)” column.
Trait Name | Trait Full Name | Panel | Author | Year | Cases* | Controls | TAG Set Threshold |
CSEA p (chi2) |
---|---|---|---|---|---|---|---|---|
Allergies | Allergies | MTC | Ferreira | 2017 | NA | 180709 | 5.00e-2 | 1.59e-2 |
Allergies | Allergies | MTC | Ferreira | 2017 | NA | 180709 | 1.00e-2 | 8.64e-4 |
Allergies | Allergies | MTC | Ferreira | 2017 | NA | 180709 | 1.00e-3 | 9.45e-5 |
Allergies | Allergies | MTC | Ferreira | 2017 | NA | 180709 | 1.00e-4 | 1.42e-3 |
Allergies | Allergies | MTC | Ferreira | 2017 | NA | 180709 | 1.00e-5 | 2.63e-3 |
Asthma | Asthma | MTC | Demenais | 2017 | 19954 | 107715 | 1.00e-2 | 5.33e-4 |
Asthma | Asthma | MTC | Demenais | 2017 | 19954 | 107715 | 1.00e-3 | 6.66e-7 |
Asthma | Asthma | MTC | Demenais | 2017 | 19954 | 107715 | 1.00e-4 | 8.72e-8 |
Asthma | Asthma | MTC | Demenais | 2017 | 19954 | 107715 | 1.00e-5 | 4.09e-4 |
BMI | Body Mass Index | MTC | Yang | 2012 | NA | 133154 | 1.00e-3 | 3.39e-2 |
CD | Crohn's disease | MTC | Franke | 2010 | 6333 | 15056 | 1.00e-4 | 1.42e-2 |
CD | Crohn's disease | MTC | Franke | 2010 | 6333 | 15056 | 1.00e-5 | 1.15e-2 |
CD | Crohn's disease | MTC | Lee | 2017 | 1762 | 972 | 1.00e-4 | 4.88e-3 |
Cross Disorder Brain | Cross Disorder Brain | MTC | PGC | 2013 | 33332 | 27888 | 1.00e-4 | 2.02e-4 |
Cross Disorder Brain | Cross Disorder Brain | MTC | PGC | 2013 | 33332 | 27888 | 1.00e-5 | 3.26e-4 |
Depressive Symptoms | Depressive Symptoms | ETC | Okbay | 2016 | 122210 | 58835 | 1.00e-2 | 2.48e-2 |
Depressive Symptoms | Depressive Symptoms | ETC | Okbay | 2016 | 122210 | 58835 | 1.00e-3 | 7.15e-3 |
Gait Speed | Gait Speed | MTC | Ben-Avraham | 2017 | NA | 31478 | 5.00e-2 | 3.51e-2 |
Height | Height | MTC | Lango-Allen | 2010 | NA | 133653 | 1.00e-3 | 3.08e-2 |
Height | Height | MTC | Lango-Allen | 2010 | NA | 133653 | 1.00e-4 | 2.98e-3 |
Height | Height | MTC | Lango-Allen | 2010 | NA | 133653 | 1.00e-5 | 4.60e-3 |
Hemoglobin A1c | Hemoglobin A1c | ETC | Soranzo | 2010 | NA | 46368 | 1.00e-4 | 1.29e-2 |
MDD | Major Depressive Disorder | ETC | Wray | 2018 | 16823 | 25632 | 5.00e-2 | 1.03e-2 |
MDD | Major Depressive Disorder | ETC | Wray | 2018 | 16823 | 25632 | 1.00e-2 | 3.94e-2 |
MDD | Major Depressive Disorder | ETC | Wray | 2018 | 16823 | 25632 | 1.00e-3 | 4.81e-2 |
MDD | Major Depressive Disorder | ETC | Wray | 2018 | 16823 | 25632 | 1.00e-4 | 8.31e-3 |
MDD | Major Depressive Disorder | ETC | Wray | 2018 | 16823 | 25632 | 1.00e-5 | 5.08e-3 |
MS | Multiple Sclerosis | MTC | Hafler | 2007 | 931 | 2431 | 1.00e-3 | 1.13e-2 |
MS | Multiple Sclerosis | MTC | Hafler | 2007 | 931 | 2431 | 1.00e-4 | 7.12e-4 |
MS | Multiple Sclerosis | MTC | Hafler | 2007 | 931 | 2431 | 1.00e-5 | 2.74e-3 |
Neuroticism | Neuroticism | MTC | De-Moor | 2012 | NA | 17375 | 5.00e-2 | 3.63e-3 |
Neuroticism Symptoms | Neuroticism Symptoms | ETC | Okbay | 2016 | NA | 170911 | 5.00e-2 | 1.08e-2 |
Neuroticism Symptoms | Neuroticism Symptoms | ETC | Okbay | 2016 | NA | 170911 | 1.00e-2 | 1.64e-2 |
Primary Sclerosing Cholangitis | Primary Sclerosing Cholangitis | MTC | Ji | 2017 | 2871 | 12019 | 5.00e-2 | 1.80e-4 |
Primary Sclerosing Cholangitis | Primary Sclerosing Cholangitis | MTC | Ji | 2017 | 2871 | 12019 | 1.00e-2 | 2.54e-5 |
Primary Sclerosing Cholangitis | Primary Sclerosing Cholangitis | MTC | Ji | 2017 | 2871 | 12019 | 1.00e-3 | 1.91e-6 |
Primary Sclerosing Cholangitis | Primary Sclerosing Cholangitis | MTC | Ji | 2017 | 2871 | 12019 | 1.00e-4 | 3.29e-9 |
Primary Sclerosing Cholangitis | Primary Sclerosing Cholangitis | MTC | Ji | 2017 | 2871 | 12019 | 1.00e-5 | 2.56e-9 |
Red Blood Cell Distribution Width | Red Blood Cell Distribution Width | MTC | Pilling | 2017 | NA | 116666 | 1.00e-2 | 4.48e-2 |
Red Blood Cell Distribution Width | Red Blood Cell Distribution Width | MTC | Pilling | 2017 | NA | 116666 | 1.00e-3 | 8.58e-3 |
Red Blood Cell Distribution Width | Red Blood Cell Distribution Width | MTC | Pilling | 2017 | NA | 116666 | 1.00e-4 | 8.51e-3 |
Red Blood Cell Distribution Width | Red Blood Cell Distribution Width | MTC | Pilling | 2017 | NA | 116666 | 1.00e-5 | 5.30e-3 |
Rheumatoid Arthritis | Rheumatoid Arthritis | ETC | Stahl | 2010 | 5539 | 20169 | 5.00e-2 | 2.06e-2 |
Rheumatoid Arthritis | Rheumatoid Arthritis | ETC | Stahl | 2010 | 5539 | 20169 | 1.00e-2 | 3.77e-3 |
Rheumatoid Arthritis | Rheumatoid Arthritis | ETC | Stahl | 2010 | 5539 | 20169 | 1.00e-5 | 4.57e-2 |
Serum Urate | Serum Urate | MTC | Kottgen | 2013 | NA | 110347 | 5.00e-2 | 1.44e-2 |
Serum Urate | Serum Urate | MTC | Kottgen | 2013 | NA | 110347 | 1.00e-2 | 1.02e-2 |
Serum Urate | Serum Urate | MTC | Kottgen | 2013 | NA | 110347 | 1.00e-3 | 1.05e-4 |
Serum Urate | Serum Urate | MTC | Kottgen | 2013 | NA | 110347 | 1.00e-4 | 2.75e-4 |
Serum Urate | Serum Urate | MTC | Kottgen | 2013 | NA | 110347 | 1.00e-5 | 2.44e-3 |
Subjective Well Being | Subjective Well Being | ETC | Okbay | 2016 | NA | 298420 | 1.00e-4 | 4.35e-2 |
UC | Ulcerative Colitis | MTC | Anderson | 2011 | 6687 | 19718 | 1.00e-2 | 7.04e-4 |
Albuminuria | Urinary Albumin to Creatinine Ratio In Nondiabetics | MTC | Teumer | 2016 | NA | 46051 | 1.00e-4 | 3.98e-3 |
Alcohol Consumption | Alcohol Consumption Women Continuous | MTC | Schumann | 2016 | NA | 42900 | 1.00e-2 | 2.07e-2 |
Alcohol Consumption | Alcohol Consumption Women Continuous | MTC | Schumann | 2016 | NA | 42900 | 1.00e-3 | 1.04e-2 |
Anthropometric Extremes | Extreme Height | MTC | Berndt | 2013 | 8097 | 8099 | 1.00e-3 | 4.46e-3 |
Anthropometric Extremes | Extreme Height | MTC | Berndt | 2013 | 8097 | 8099 | 1.00e-4 | 3.11e-3 |
Anthropometrics Sex Stratified | Height Men | MTC | Randall | 2013 | NA | 60856 | 1.00e-2 | 2.61e-2 |
Anthropometrics Sex Stratified | Height Men | MTC | Randall | 2013 | NA | 60856 | 1.00e-3 | 3.83e-2 |
Anthropometrics Sex Stratified | Height Women | MTC | Randall | 2013 | NA | 73137 | 1.00e-3 | 2.34e-2 |
Anthropometrics Sex Stratified | Height Women | MTC | Randall | 2013 | NA | 73137 | 1.00e-4 | 1.43e-2 |
Anthropometrics Sex Stratified | Height Women | MTC | Randall | 2013 | NA | 73137 | 1.00e-5 | 8.33e-3 |
Anthropometrics Sex Stratified | Hip Circumference Adjusted For BMI Women | MTC | Randall | 2013 | NA | 43316 | 1.00e-3 | 1.88e-2 |
Anthropometrics Sex Stratified | Hip Circumference Women | MTC | Randall | 2013 | NA | 43316 | 5.00e-2 | 1.04e-3 |
Anthropometrics Sex Stratified | Waist Circumference Adjusted For BMI Men | MTC | Randall | 2013 | NA | 36231 | 5.00e-2 | 2.42e-2 |
Anthropometrics Sex Stratified | Waist Circumference Women | MTC | Randall | 2013 | NA | 45192 | 5.00e-2 | 1.69e-2 |
Anthropometrics Sex Stratified | Waist Circumference Women | MTC | Randall | 2013 | NA | 45192 | 1.00e-2 | 1.00e-2 |
Anthropometrics Sex Stratified | Waist Hip Ratio Men | MTC | Randall | 2013 | NA | 34629 | 1.00e-2 | 1.58e-2 |
Anthropometrics Sex Stratified | Weight Women | MTC | Randall | 2013 | NA | 73137 | 1.00e-3 | 1.92e-2 |
Anthropometrics Sex Stratified | Weight Women | MTC | Randall | 2013 | NA | 73137 | 1.00e-4 | 6.36e-3 |
Anthropometrics Sex Stratified | Weight Women | MTC | Randall | 2013 | NA | 73137 | 1.00e-5 | 7.17e-3 |
Anxiety | Anxiety Continuous | ETC | Otowa | 2016 | NA | 18186 | 1.00e-3 | 2.21e-2 |
Blood Cells | Lymphocyte Counts | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-3 | 2.76e-2 |
Blood Cells | Lymphocyte Counts | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-5 | 3.98e-3 |
Blood Cells | Mean Corpuscular Hemoglobin | MTC | Ferreira | 2009 | NA | 6015 | 5.00e-2 | 3.15e-2 |
Blood Cells | Mean Corpuscular Hemoglobin | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-2 | 6.87e-4 |
Blood Cells | Mean Corpuscular Hemoglobin | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-3 | 2.14e-4 |
Blood Cells | Mean Corpuscular Hemoglobin | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-4 | 1.19e-3 |
Blood Cells | Mean Erythrocyte Cell Volume | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-2 | 2.12e-3 |
Blood Cells | Mean Erythrocyte Cell Volume | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-3 | 1.97e-2 |
Blood Cells | Mean Erythrocyte Cell Volume | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-4 | 2.24e-3 |
Blood Cells | Neutrophil Counts | MTC | Ferreira | 2009 | NA | 6015 | 5.00e-2 | 4.27e-2 |
Blood Cells | Neutrophil Counts | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-2 | 4.64e-3 |
Blood Cells | Total Blood Hemoglobin | MTC | Ferreira | 2009 | NA | 6015 | 5.00e-2 | 9.21e-3 |
Blood Cells | Total Blood Hemoglobin | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-2 | 4.64e-2 |
Blood Cells | Total Blood Hemoglobin | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-3 | 2.10e-3 |
Blood Cells | White Blood Cell Counts | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-2 | 2.16e-2 |
Blood Lipids | Low Density Lipoprotein | ETC | Teslovich | 2010 | NA | 95454 | 5.00e-2 | 2.29e-2 |
Blood Lipids | Low Density Lipoprotein | ETC | Teslovich | 2010 | NA | 95454 | 1.00e-2 | 6.37e-3 |
Blood Lipids | Low Density Lipoprotein | ETC | Teslovich | 2010 | NA | 95454 | 1.00e-3 | 7.03e-3 |
Blood Lipids | Low Density Lipoprotein | ETC | Teslovich | 2010 | NA | 95454 | 1.00e-4 | 7.93e-3 |
Blood Lipids | Total Cholesterol | ETC | Teslovich | 2010 | NA | 100184 | 5.00e-2 | 3.64e-2 |
Blood Lipids | Total Cholesterol | ETC | Teslovich | 2010 | NA | 100184 | 1.00e-2 | 9.10e-3 |
Blood Lipids | Total Cholesterol | ETC | Teslovich | 2010 | NA | 100184 | 1.00e-3 | 1.39e-2 |
Blood Lipids | Total Cholesterol | ETC | Teslovich | 2010 | NA | 100184 | 1.00e-4 | 3.07e-2 |
Blood Lipids | Total Cholesterol | ETC | Teslovich | 2010 | NA | 100184 | 1.00e-5 | 4.94e-2 |
Blood Lipids | Low Density Lipoprotein GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-2 | 1.57e-2 |
Blood Lipids | Low Density Lipoprotein GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-3 | 2.70e-2 |
Blood Lipids | Low Density Lipoprotein GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-4 | 1.62e-2 |
Blood Lipids | Total Cholesterol GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 5.00e-2 | 2.80e-2 |
Blood Lipids | Total Cholesterol GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-2 | 2.62e-3 |
Blood Lipids | Total Cholesterol GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-3 | 3.45e-3 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Active European | MTC | GIANT | 2017 | NA | 234069 | 5.00e-2 | 1.07e-2 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Active European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-2 | 4.44e-4 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Active European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-3 | 1.32e-2 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Adjusted For Physical Activity European | MTC | GIANT | 2017 | NA | 234069 | 5.00e-2 | 1.86e-2 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Adjusted For Physical Activity European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-2 | 1.21e-2 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Adjusted For Physical Activity European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-3 | 1.32e-2 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Adjusted For Physical Activity European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-4 | 7.59e-3 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Adjusted For Physical Activity European Men | MTC | GIANT | 2017 | NA | 104666 | 5.00e-2 | 3.76e-2 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Adjusted For Physical Activity European Men | MTC | GIANT | 2017 | NA | 104666 | 1.00e-2 | 1.22e-2 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Adjusted For Physical Activity European Men | MTC | GIANT | 2017 | NA | 104666 | 1.00e-3 | 1.64e-2 |
BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Active European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-3 | 4.37e-2 |
BMI Smoking Adjusted | Waist Circumference Adjusted BMI Adjusted Smoking European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-2 | 1.93e-2 |
BMI Smoking Adjusted | Waist Circumference Adjusted BMI Adjusted Smoking European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-3 | 8.70e-3 |
BMI Smoking Adjusted | Waist Circumference Adjusted BMI Adjusted Smoking European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-4 | 2.32e-3 |
BMI Smoking Adjusted | Waist Circumference Adjusted BMI Adjusted Smoking European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-5 | 5.66e-3 |
BMI Smoking Adjusted | Waist Circumference Adjusted BMI Adjusted Smoking Men European | MTC | GIANT | 2017 | NA | 104666 | 5.00e-2 | 3.68e-2 |
BMI Smoking Adjusted | Waist Circumference Adjusted BMI Adjusted Smoking Men European | MTC | GIANT | 2017 | NA | 104666 | 1.00e-2 | 4.60e-3 |
BMI Smoking Adjusted | Waist Circumference Adjusted BMI Adjusted Smoking Men European | MTC | GIANT | 2017 | NA | 104666 | 1.00e-3 | 5.46e-3 |
BMI Smoking Adjusted | Waist Circumference Adjusted BMI Adjusted Smoking Men European | MTC | GIANT | 2017 | NA | 104666 | 1.00e-4 | 1.81e-2 |
Ectopic Fat Traits | Pericardial Adipose Tissue Volume Adjusted For Height Weight All | MTC | Chu | 2017 | NA | 7324 | 1.00e-3 | 1.43e-2 |
Facial Shape | Mod15 | MTC | Claes | 2018 | NA | 2329 | 1.00e-3 | 4.89e-2 |
Glycemic Traits BMI Corrected | Fasting Insulin Interaction With BMI | MTC | Manning | 2012 | NA | 51750 | 1.00e-2 | 4.42e-3 |
Glycemic Traits BMI Corrected | Fasting Insulin Interaction With BMI | MTC | Manning | 2012 | NA | 51750 | 1.00e-3 | 4.89e-2 |
Hemoglobin A1c | Hemoglobin A1c European | MTC | Wheeler | 2017 | NA | 159940 | 1.00e-2 | 3.68e-2 |
Hemoglobin A1c | Hemoglobin A1c European | MTC | Wheeler | 2017 | NA | 159940 | 1.00e-3 | 3.08e-2 |
Hemoglobin A1c | Hemoglobin A1c European | MTC | Wheeler | 2017 | NA | 159940 | 1.00e-4 | 3.41e-3 |
Hemoglobin A1c | Hemoglobin A1c European | MTC | Wheeler | 2017 | NA | 159940 | 1.00e-5 | 1.29e-2 |
Inflammatory Bowel Disease European | Crohn's disease | ETC | Liu | 2015 | 5956 | 14927 | 1.00e-3 | 7.19e-3 |
Inflammatory Bowel Disease European | Crohn's disease | ETC | Liu | 2015 | 5956 | 14927 | 1.00e-4 | 5.74e-3 |
Inflammatory Bowel Disease European | Crohn's disease | ETC | Liu | 2015 | 5956 | 14927 | 1.00e-5 | 4.67e-2 |
Inflammatory Bowel Disease European | Inflammatory Bowel Disease | ETC | Liu | 2015 | 12882 | 21770 | 1.00e-3 | 4.01e-2 |
Inflammatory Bowel Disease European | Inflammatory Bowel Disease | ETC | Liu | 2015 | 12882 | 21770 | 1.00e-4 | 1.46e-2 |
Inflammatory Bowel Disease European | Inflammatory Bowel Disease | ETC | Liu | 2015 | 12882 | 21770 | 1.00e-5 | 1.95e-2 |
Inflammatory Bowel Disease European | Ulcerative Colitis | ETC | Liu | 2015 | 6968 | 20464 | 1.00e-3 | 4.18e-3 |
Inflammatory Bowel Disease European | Ulcerative Colitis | ETC | Liu | 2015 | 6968 | 20464 | 1.00e-4 | 5.37e-3 |
Lipoprotein Concentrations | Low Density Lipoprotein | MTC | Kathiresan | 2009 | NA | 19840 | 1.00e-2 | 3.91e-2 |
Lipoprotein Concentrations | Low Density Lipoprotein | MTC | Kathiresan | 2009 | NA | 19840 | 1.00e-3 | 3.71e-2 |
Lymphocyte Subsets | CD3 Level | MTC | Ferreira | 2010 | NA | 2538 | 5.00e-2 | 3.01e-3 |
Lymphocyte Subsets | CD3 Level | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-3 | 1.29e-2 |
Lymphocyte Subsets | CD4:CD8 Ratio | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-3 | 2.85e-3 |
Lymphocyte Subsets | CD4:CD8 Ratio | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-4 | 1.05e-2 |
Lymphocyte Subsets | CD4 Level | MTC | Ferreira | 2010 | NA | 2538 | 5.00e-2 | 3.47e-2 |
Lymphocyte Subsets | CD8 Level | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-2 | 2.17e-2 |
Lymphocyte Subsets | CD8 Level | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-3 | 1.15e-2 |
Lymphocyte Subsets | CD8 Level | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-4 | 1.95e-2 |
New Onset Diabetes | New Onset Diabetes After Drugs, European American | MTC | Chang | 2018 | 138 | 414 | 5.00e-2 | 1.55e-2 |
Pubertal Anthropometrics | Height 10 Year Females | MTC | Cousminer | 2013 | NA | 14040 | 5.00e-2 | 4.40e-2 |
Pubertal Anthropometrics | Height 10 Year Females And 12 Year Males | MTC | Cousminer | 2013 | NA | 14040 | 5.00e-2 | 3.49e-2 |
Pubertal Anthropometrics | Height 12 Year Males | MTC | Cousminer | 2013 | NA | 14040 | 5.00e-2 | 3.43e-2 |
Pubertal Anthropometrics | Height 12 Year Males | MTC | Cousminer | 2013 | NA | 14040 | 1.00e-3 | 4.71e-3 |
Rheumatoid Arthritis | Rheumatoid Arthritis European | MTC | Okada | 2014 | 14361 | 43923 | 5.00e-2 | 4.92e-4 |
Rheumatoid Arthritis | Rheumatoid Arthritis European | MTC | Okada | 2014 | 14361 | 43923 | 1.00e-2 | 8.19e-5 |
Rheumatoid Arthritis | Rheumatoid Arthritis European | MTC | Okada | 2014 | 14361 | 43923 | 1.00e-3 | 1.49e-5 |
Rheumatoid Arthritis | Rheumatoid Arthritis European | MTC | Okada | 2014 | 14361 | 43923 | 1.00e-4 | 7.97e-6 |
Rheumatoid Arthritis | Rheumatoid Arthritis European | MTC | Okada | 2014 | 14361 | 43923 | 1.00e-5 | 2.47e-4 |
Sleep Duration | Average Sleep Duration | MTC | Jones | 2016 | NA | 127573 | 1.00e-2 | 6.28e-3 |
Circadian Rhythm | Sleep Chronotype | MTC | Jones | 2016 | NA | 127898 | 1.00e-2 | 4.89e-2 |
Tanner Stage | Tanner Stage Females | MTC | Cousminer | 2014 | NA | 6144 | 1.00e-3 | 7.10e-3 |
Waist Format 1 | Hip Circumference European | MTC | Shungin | 2015 | NA | 143480 | 1.00e-3 | 2.65e-4 |
Waist Format 1 | Hip Circumference European | MTC | Shungin | 2015 | NA | 143480 | 1.00e-4 | 1.44e-2 |
Waist Format 1 | Hip Circumference Males European | MTC | Shungin | 2015 | NA | 56910 | 1.00e-2 | 5.31e-3 |
Waist Format 1 | Hip Circumference Males European | MTC | Shungin | 2015 | NA | 56910 | 1.00e-3 | 2.86e-2 |
Waist Format 1 | Waist Circumference Males European | MTC | Shungin | 2015 | NA | 56910 | 1.00e-2 | 1.19e-2 |
Waist Format 1 | Waist Circumference Males European | MTC | Shungin | 2015 | NA | 56910 | 1.00e-3 | 3.27e-2 |
Waist Format 2 | Hip Circumference Adjusted For BMI European | MTC | Shungin | 2015 | NA | 143480 | 1.00e-2 | 1.34e-2 |
Waist Format 2 | Hip Circumference Adjusted For BMI European | MTC | Shungin | 2015 | NA | 143480 | 1.00e-3 | 7.04e-5 |
Waist Format 2 | Hip Circumference Adjusted For BMI European | MTC | Shungin | 2015 | NA | 143480 | 1.00e-4 | 3.19e-5 |
Waist Format 2 | Hip Circumference Adjusted For BMI European | MTC | Shungin | 2015 | NA | 143480 | 1.00e-5 | 9.76e-6 |
Waist Format 2 | Hip Circumference Adjusted For BMI Females European | MTC | Shungin | 2015 | NA | 86570 | 5.00e-2 | 1.88e-2 |
Waist Format 2 | Hip Circumference Adjusted For BMI Females European | MTC | Shungin | 2015 | NA | 86570 | 1.00e-2 | 2.96e-2 |
Waist Format 2 | Hip Circumference Adjusted For BMI Females European | MTC | Shungin | 2015 | NA | 86570 | 1.00e-3 | 2.62e-5 |
Waist Format 2 | Hip Circumference Adjusted For BMI Females European | MTC | Shungin | 2015 | NA | 86570 | 1.00e-4 | 1.28e-6 |
Waist Format 2 | Hip Circumference Adjusted For BMI Females European | MTC | Shungin | 2015 | NA | 86570 | 1.00e-5 | 1.20e-6 |
Waist Format 2 | Hip Circumference Adjusted For BMI Males European | MTC | Shungin | 2015 | NA | 56910 | 5.00e-2 | 4.31e-2 |
Waist Format 2 | Hip Circumference Adjusted For BMI Males European | MTC | Shungin | 2015 | NA | 56910 | 1.00e-3 | 7.94e-4 |
Waist Format 2 | Hip Circumference Adjusted For BMI Males European | MTC | Shungin | 2015 | NA | 56910 | 1.00e-4 | 7.24e-4 |
Waist Format 2 | Hip Circumference Adjusted For BMI Males European | MTC | Shungin | 2015 | NA | 56910 | 1.00e-5 | 5.89e-3 |
Waist Format 2 | Waist Circumference Adjusted For BMI European | MTC | Shungin | 2015 | NA | 143480 | 1.00e-2 | 2.60e-4 |
Waist Format 2 | Waist Circumference Adjusted For BMI European | MTC | Shungin | 2015 | NA | 143480 | 1.00e-3 | 1.09e-5 |
Waist Format 2 | Waist Circumference Adjusted For BMI European | MTC | Shungin | 2015 | NA | 143480 | 1.00e-4 | 3.12e-3 |
Waist Format 2 | Waist Circumference Adjusted For BMI Females European | MTC | Shungin | 2015 | NA | 86570 | 1.00e-2 | 3.71e-2 |
Waist Format 2 | Waist Circumference Adjusted For BMI Males European | MTC | Shungin | 2015 | NA | 56910 | 1.00e-2 | 5.85e-5 |
Waist Format 2 | Waist Circumference Adjusted For BMI Males European | MTC | Shungin | 2015 | NA | 56910 | 1.00e-3 | 6.22e-3 |
Waist Format 2 | Waist Circumference Adjusted For BMI Males European | MTC | Shungin | 2015 | NA | 56910 | 1.00e-4 | 4.85e-3 |
Waist Format 2 | Waist Circumference Adjusted For BMI Males European | MTC | Shungin | 2015 | NA | 56910 | 1.00e-5 | 1.73e-2 |
SCZ | Schizophrenia | ETC | Ripke | 2014 | 32405 | 42221+í | 1.00e-3 | 3.97e-2 |
SCZ | Schizophrenia | ETC | Ripke | 2014 | 32405 | 42221+í | 1.00e-4 | 2.01e-2 |
SCZ | Schizophrenia | ETC | Ripke | 2014 | 32405 | 42221+í | 1.00e-5 | 1.29e-4 |
T1D | Type 1 Diabetes | ETC | Bradfield | 2011 | 9934 | 16956 | 5.00e-2 | 4.67e-6 |
T1D | Type 1 Diabetes | ETC | Bradfield | 2011 | 9934 | 16956 | 1.00e-2 | 1.13e-7 |
T1D | Type 1 Diabetes | ETC | Bradfield | 2011 | 9934 | 16956 | 1.00e-3 | 3.61e-8 |
T1D | Type 1 Diabetes | ETC | Bradfield | 2011 | 9934 | 16956 | 1.00e-4 | 1.80e-8 |
T1D | Type 1 Diabetes | ETC | Bradfield | 2011 | 9934 | 16956 | 1.00e-5 | 4.97e-8 |
HGB | Hemoglobin Concentration | ETC | Astle | 2016 | NA | 173480 | 1.00e-3 | 7.42e-3 |
HGB | Hemoglobin Concentration | ETC | Astle | 2016 | NA | 173480 | 1.00e-4 | 3.54e-3 |
HGB | Hemoglobin Concentration | ETC | Astle | 2016 | NA | 173480 | 1.00e-5 | 7.59e-5 |
MCHC | Mean Corpuscular Hemoglobin Concentration | ETC | Astle | 2016 | NA | 173480 | 1.00e-3 | 1.81e-2 |
MCHC | Mean Corpuscular Hemoglobin Concentration | ETC | Astle | 2016 | NA | 173480 | 1.00e-4 | 7.32e-3 |
MCHC | Mean Corpuscular Hemoglobin Concentration | ETC | Astle | 2016 | NA | 173480 | 1.00e-5 | 1.10e-2 |
PBC | Primary Biliary Cirrhosis | ETC | Cordell | 2015 | 2764 | 10475 | 5.00e-2 | 4.25e-6 |
PBC | Primary Biliary Cirrhosis | ETC | Cordell | 2015 | 2764 | 10475 | 1.00e-2 | 1.11e-6 |
PBC | Primary Biliary Cirrhosis | ETC | Cordell | 2015 | 2764 | 10475 | 1.00e-3 | 2.24e-7 |
PBC | Primary Biliary Cirrhosis | ETC | Cordell | 2015 | 2764 | 10475 | 1.00e-4 | 1.94e-5 |
PBC | Primary Biliary Cirrhosis | ETC | Cordell | 2015 | 2764 | 10475 | 1.00e-5 | 1.66e-6 |
SLE | Systemic Lupus Erythematosus | ETC | Bentham | 2015 | 7219 | 15991 | 5.00e-2 | 5.65e-7 |
SLE | Systemic Lupus Erythematosus | ETC | Bentham | 2015 | 7219 | 15991 | 1.00e-2 | 2.44e-8 |
SLE | Systemic Lupus Erythematosus | ETC | Bentham | 2015 | 7219 | 15991 | 1.00e-3 | 8.40e-8 |
SLE | Systemic Lupus Erythematosus | ETC | Bentham | 2015 | 7219 | 15991 | 1.00e-4 | 7.96e-6 |
SLE | Systemic Lupus Erythematosus | ETC | Bentham | 2015 | 7219 | 15991 | 1.00e-5 | 1.15e-6 |
T1D CA | Type1Diabetes (Childhood adiposity age < 17) | ETC | Censin | 2017 | 5913 | 8828 | 5.00e-2 | 9.46e-4 |
T1D CA | Type1Diabetes (Childhood adiposity age < 17) | ETC | Censin | 2017 | 5913 | 8828 | 1.00e-2 | 3.06e-5 |
T1D CA | Type1Diabetes (Childhood adiposity age < 17) | ETC | Censin | 2017 | 5913 | 8828 | 1.00e-3 | 4.83e-8 |
T1D CA | Type1Diabetes (Childhood adiposity age < 17) | ETC | Censin | 2017 | 5913 | 8828 | 1.00e-4 | 6.90e-10 |
T1D CA | Type1Diabetes (Childhood adiposity age < 17) | ETC | Censin | 2017 | 5913 | 8828 | 1.00e-5 | 5.84e-10 |
MS | Multiple Sclerosis | ETC | Patsopoulos | 2017 | 14802 | 26703 | 5.00e-2 | 7.81e-9 |
MS | Multiple Sclerosis | ETC | Patsopoulos | 2017 | 14802 | 26703 | 1.00e-2 | 2.40e-9 |
MS | Multiple Sclerosis | ETC | Patsopoulos | 2017 | 14802 | 26703 | 1.00e-3 | 4.02e-10 |
MS | Multiple Sclerosis | ETC | Patsopoulos | 2017 | 14802 | 26703 | 1.00e-4 | 8.71e-9 |
MS | Multiple Sclerosis | ETC | Patsopoulos | 2017 | 14802 | 26703 | 1.00e-5 | 2.23e-10 |
SCZ | Schizophrenia | ETC | Pardinas | 2018 | 40675 | 64643 | 1.00e-4 | 3.30e-3 |
SCZ | Schizophrenia | ETC | Pardinas | 2018 | 40675 | 64643 | 1.00e-5 | 8.11e-3 |
CEL | Celiac Disease | ETC | Trynka | 2011 | 12041 | 12228 | 5.00e-2 | 4.35e-3 |
CEL | Celiac Disease | ETC | Trynka | 2011 | 12041 | 12228 | 1.00e-2 | 7.97e-4 |
CEL | Celiac Disease | ETC | Trynka | 2011 | 12041 | 12228 | 1.00e-3 | 1.16e-2 |
CEL | Celiac Disease | ETC | Trynka | 2011 | 12041 | 12228 | 1.00e-5 | 2.57e-2 |
Handedness | Handedness, right-handed vs non-right-handed | ETC | Kovel | 2019 | 293857 | 37180 | 5.00e-2 | 4.13e-2 |
Sleep | Sleep number of episodes | ETC | Jones | 2019 | NA | 84810 | 1.00e-2 | 4.32e-2 |
Facial attractiveness | Facial attractiveness of females, female raters | ETC | Hu | 2019 | NA | 2062 | 5.00e-2 | 3.21e-2 |
Asthma | Asthma, adult-onset | ETC | Ferreira | 2019 | 26582 | 300671 | 5.00e-2 | 2.75e-3 |
Asthma | Asthma, adult-onset | ETC | Ferreira | 2019 | 26582 | 300671 | 1.00e-2 | 1.64e-2 |
Asthma | Asthma, adult-onset | ETC | Ferreira | 2019 | 26582 | 300671 | 1.00e-3 | 3.54e-2 |
Asthma | Asthma, childhood-onset | ETC | Ferreira | 2019 | 13962 | 300671 | 5.00e-2 | 1.72e-2 |
Asthma | Asthma, childhood-onset | ETC | Ferreira | 2019 | 13962 | 300671 | 1.00e-2 | 5.70e-4 |
Asthma | Asthma, childhood-onset | ETC | Ferreira | 2019 | 13962 | 300671 | 1.00e-3 | 7.20e-3 |
Asthma | Asthma, childhood-onset | ETC | Ferreira | 2019 | 13962 | 300671 | 1.00e-4 | 2.31e-3 |
Asthma | Asthma, childhood-onset | ETC | Ferreira | 2019 | 13962 | 300671 | 1.00e-5 | 2.03e-3 |
Na/K ratio | Urinary sodium to potassium ratio | ETC | Zanetti | 2019 | NA | 108942 | 1.00e-4 | 6.76e-3 |
Vitiligo | Vitiligo late onset | ETC | Jin | 2019 | 1467 | 19156 | 5.00e-2 | 3.75e-5 |
Vitiligo | Vitiligo late onset | ETC | Jin | 2019 | 1467 | 19156 | 1.00e-2 | 1.89e-6 |
Vitiligo | Vitiligo late onset | ETC | Jin | 2019 | 1467 | 19156 | 1.00e-3 | 2.37e-6 |
Vitiligo | Vitiligo late onset | ETC | Jin | 2019 | 1467 | 19156 | 1.00e-4 | 1.16e-3 |
Vitiligo | Vitiligo late onset | ETC | Jin | 2019 | 1467 | 19156 | 1.00e-5 | 2.15e-2 |
Vitiligo | Vitiligo early onset | ETC | Jin | 2019 | 704 | 9031 | 1.00e-2 | 2.77e-2 |
Vitiligo | Vitiligo early onset | ETC | Jin | 2019 | 704 | 9031 | 1.00e-3 | 7.19e-3 |
Vitiligo | Vitiligo early onset | ETC | Jin | 2019 | 704 | 9031 | 1.00e-4 | 5.32e-3 |
Vitiligo | Vitiligo early onset | ETC | Jin | 2019 | 704 | 9031 | 1.00e-5 | 2.71e-2 |
Osteoarthritis | Osteoarthritis | ETC | Tachmazidou | 2019 | 77052 | 378169 | 1.00e-3 | 8.88e-3 |
Osteoarthritis | Osteoarthritis | ETC | Tachmazidou | 2019 | 77052 | 378169 | 1.00e-4 | 1.74e-2 |
Osteoarthritis | Osteoarthritis of the hip or knee | ETC | Tachmazidou | 2019 | 39427 | 378169 | 1.00e-3 | 3.26e-2 |
Osteoarthritis | Knee osteoarthritis | ETC | Tachmazidou | 2019 | 24955 | 376169 | 1.00e-2 | 1.23e-3 |
Osteoarthritis | Knee osteoarthritis | ETC | Tachmazidou | 2019 | 24955 | 376169 | 1.00e-3 | 5.11e-4 |
Depression | Depressive-symptoms | ETC | Baselmans | 2019 | NA | 1067913 | 1.00e-2 | 3.20e-2 |
Depression | Depressive-symptoms | ETC | Baselmans | 2019 | NA | 1067913 | 1.00e-3 | 9.67e-3 |
Depression | Depressive-symptoms | ETC | Baselmans | 2019 | NA | 1067913 | 1.00e-4 | 1.14e-2 |
Depression | Depressive-symptoms | ETC | Baselmans | 2019 | NA | 1067913 | 1.00e-5 | 8.10e-3 |
Positive affect | Positive affect | ETC | Baselmans | 2019 | NA | 410603 | 1.00e-4 | 1.66e-2 |
Positive affect | Positive affect | ETC | Baselmans | 2019 | NA | 410603 | 1.00e-5 | 3.99e-2 |
Life satisfaction | Life satisfaction | ETC | Baselmans | 2019 | NA | 80852 | 1.00e-2 | 1.31e-2 |
Life satisfaction | Life satisfaction | ETC | Baselmans | 2019 | NA | 80852 | 1.00e-3 | 3.99e-2 |
Psoriatic arthritis | Psoriatic arthritis | ETC | Aterido | 2018 | 744 | 1454 | 1.00e-3 | 3.99e-2 |
Asthma | Asthma, moderate or severe | ETC | Shrine | 2018 | 5414 | 21471 | 1.00e-3 | 3.22e-2 |
Asthma | Asthma, moderate or severe | ETC | Shrine | 2018 | 5414 | 21471 | 1.00e-4 | 9.16e-3 |
Hippocampal volume | Hippocampal tail volume | ETC | Meer | 2018 | NA | 21297 | 5.00e-2 | 3.16e-3 |
Presubiculum volume | Presubiculum volume | ETC | Meer | 2018 | NA | 21297 | 1.00e-3 | 8.51e-4 |
Medication use | Medication use (drugs for peptic ulcer and gastro-oesophageal reflux disease) | ETC | Wu Y | 2019 | 53,137 | 79,230 | 1.00e-3 | 3.57e-3 |
Medication use | Medication use (drugs for peptic ulcer and gastro-oesophageal reflux disease) | ETC | Wu Y | 2019 | 53,137 | 79,230 | 1.00e-4 | 1.97e-5 |
Medication use | Medication use (drugs for peptic ulcer and gastro-oesophageal reflux disease) | ETC | Wu Y | 2019 | 53,137 | 79,230 | 1.00e-5 | 5.09e-6 |
Medication use | Medication use (drugs used in diabetes) | ETC | Wu Y | 2019 | 15,272 | 290,641 | 1.00e-4 | 3.31e-2 |
Medication use | Medication use (diuretics) | ETC | Wu Y | 2019 | 34,453 | 194,633 | 1.00e-4 | 2.56e-2 |
Medication use | Medication use (thyroid preparations) | ETC | Wu Y | 2019 | 24,832 | 280,750 | 5.00e-2 | 4.18e-6 |
Medication use | Medication use (thyroid preparations) | ETC | Wu Y | 2019 | 24,832 | 280,750 | 1.00e-2 | 4.68e-7 |
Medication use | Medication use (thyroid preparations) | ETC | Wu Y | 2019 | 24,832 | 280,750 | 1.00e-3 | 5.39e-7 |
Medication use | Medication use (thyroid preparations) | ETC | Wu Y | 2019 | 24,832 | 280,750 | 1.00e-4 | 6.64e-7 |
Medication use | Medication use (thyroid preparations) | ETC | Wu Y | 2019 | 24,832 | 280,750 | 1.00e-5 | 2.35e-7 |
Medication use | Medication use (immunosuppressants) | ETC | Wu Y | 2019 | 3,954 | 268,648 | 5.00e-2 | 9.41e-4 |
Medication use | Medication use (immunosuppressants) | ETC | Wu Y | 2019 | 3,954 | 268,648 | 1.00e-2 | 2.41e-4 |
Medication use | Medication use (immunosuppressants) | ETC | Wu Y | 2019 | 3,954 | 268,648 | 1.00e-3 | 1.55e-3 |
Medication use | Medication use (immunosuppressants) | ETC | Wu Y | 2019 | 3,954 | 268,648 | 1.00e-4 | 1.01e-2 |
Medication use | Medication use (immunosuppressants) | ETC | Wu Y | 2019 | 3,954 | 268,648 | 1.00e-5 | 8.31e-3 |
Medication use | Medication use (anilides) | ETC | Wu Y | 2019 | 83,218 | 96,592 | 5.00e-2 | 1.01e-2 |
Medication use | Medication use (anilides) | ETC | Wu Y | 2019 | 83,218 | 96,592 | 1.00e-2 | 1.06e-2 |
Medication use | Medication use (anilides) | ETC | Wu Y | 2019 | 83,218 | 96,592 | 1.00e-3 | 5.30e-3 |
Medication use | Medication use (anilides) | ETC | Wu Y | 2019 | 83,218 | 96,592 | 1.00e-4 | 8.98e-3 |
Medication use | Medication use (anilides) | ETC | Wu Y | 2019 | 83,218 | 96,592 | 1.00e-5 | 4.84e-2 |
Medication use | Medication use (antidepressants) | ETC | Wu Y | 2019 | 33,757 | 270,405 | 1.00e-3 | 2.45e-2 |
Medication use | Medication use (adrenergics, inhalants) | ETC | Wu Y | 2019 | 28,880 | 147,565 | 1.00e-2 | 1.86e-2 |
Medication use | Medication use (adrenergics, inhalants) | ETC | Wu Y | 2019 | 28,880 | 147,565 | 1.00e-3 | 4.74e-3 |
Medication use | Medication use (adrenergics, inhalants) | ETC | Wu Y | 2019 | 28,880 | 147,565 | 1.00e-4 | 2.23e-2 |
Medication use | Medication use (glucocorticoids) | ETC | Wu Y | 2019 | 17,352 | 188,348 | 5.00e-2 | 2.08e-3 |
Medication use | Medication use (glucocorticoids) | ETC | Wu Y | 2019 | 17,352 | 188,348 | 1.00e-2 | 6.96e-3 |
Medication use | Medication use (glucocorticoids) | ETC | Wu Y | 2019 | 17,352 | 188,348 | 1.00e-3 | 7.03e-3 |
Medication use | Medication use (glucocorticoids) | ETC | Wu Y | 2019 | 17,352 | 188,348 | 1.00e-4 | 1.67e-2 |
Medication use | Medication use (glucocorticoids) | ETC | Wu Y | 2019 | 17,352 | 188,348 | 1.00e-5 | 1.17e-2 |
Varicose veins | Varicose veins | ETC | Shadrina AS | 2019 | 10,861 | 397,594 | 1.00e-2 | 6.64e-4 |
Varicose veins | Varicose veins | ETC | Shadrina AS | 2019 | 10,861 | 397,594 | 1.00e-3 | 7.78e-3 |
Varicose veins | Varicose veins | ETC | Shadrina AS | 2019 | 10,861 | 397,594 | 1.00e-4 | 6.93e-3 |
Varicose veins | Varicose veins | ETC | Shadrina AS | 2019 | 10,861 | 397,594 | 1.00e-5 | 3.71e-2 |
Urinary sodium excretion | Urinary sodium excretion | ETC | Pazoki R | 2019 | NA | 446,237 | 1.00e-4 | 1.13e-2 |
Urinary sodium excretion | Urinary sodium excretion | ETC | Pazoki R | 2019 | NA | 446,237 | 1.00e-5 | 1.86e-3 |
Urinary potassium excretion | Urinary potassium excretion | ETC | Pazoki R | 2019 | NA | 446,230 | 1.00e-2 | 7.53e-3 |
Urinary potassium excretion | Urinary potassium excretion | ETC | Pazoki R | 2019 | NA | 446,230 | 1.00e-3 | 5.03e-4 |
Urinary potassium excretion | Urinary potassium excretion | ETC | Pazoki R | 2019 | NA | 446,230 | 1.00e-4 | 1.03e-2 |
Urinary potassium excretion | Urinary potassium excretion | ETC | Pazoki R | 2019 | NA | 446,230 | 1.00e-5 | 2.71e-2 |
same-sex sexual behaviour | same-sex sexual behaviour Female | ETC | Ganna A | 2019 | NA | 220,170 | 5.00e-2 | 9.32e-3 |
same-sex sexual behaviour | same-sex sexual behaviour Female | ETC | Ganna A | 2019 | NA | 220,170 | 1.00e-2 | 3.22e-2 |
Parietal lobe volume | Parietal lobe volume | ETC | van der Lee SJ | 2019 | NA | 15,269 | 1.00e-3 | 1.35e-3 |
Albumin to creatinine ratio | Urinary albumin-to-creatinine ratio | ETC | Teumer A | 2019 | NA | 547,361 | 1.00e-3 | 9.19e-3 |
Albumin to creatinine ratio | Urinary albumin-to-creatinine ratio | ETC | Teumer A | 2019 | NA | 547,361 | 1.00e-4 | 2.47e-2 |
Asthma | Asthma | ETC | Zhu Z | 2019 | 46,802 | 347,481 | 1.00e-3 | 4.49e-3 |
Asthma | Asthma | ETC | Zhu Z | 2019 | 46,802 | 347,481 | 1.00e-4 | 1.32e-3 |
Asthma | Asthma | ETC | Zhu Z | 2019 | 46,802 | 347,481 | 1.00e-5 | 2.05e-3 |
Asthma | Asthma (adult onset) | ETC | Zhu Z | 2019 | 22,296 | 347,481 | 5.00e-2 | 1.36e-2 |
Asthma | Asthma (adult onset) | ETC | Zhu Z | 2019 | 22,296 | 347,481 | 1.00e-2 | 3.66e-2 |
Asthma | Asthma (adult onset) | ETC | Zhu Z | 2019 | 22,296 | 347,481 | 1.00e-3 | 2.69e-2 |
Urate | Urate levels | ETC | Tin A | 2019 | NA | 288,649 | 1.00e-4 | 2.58e-3 |
Urate | Urate levels | ETC | Tin A | 2019 | NA | 288,649 | 1.00e-5 | 5.03e-3 |
Joint damage | Joint damage in rheumatoid arthritis | ETC | Traylor M | 2019 | NA | 2,527 | 1.00e-2 | 2.25e-2 |
Joint damage | Joint damage in rheumatoid arthritis | ETC | Traylor M | 2019 | NA | 2,527 | 1.00e-3 | 1.58e-2 |
Body fat percentage | Body fat percentage variance | ETC | Wang H | 2019 | NA | 341,632 | 1.00e-3 | 2.08e-3 |
Body fat percentage | Body fat percentage variance | ETC | Wang H | 2019 | NA | 341,632 | 1.00e-4 | 6.35e-3 |
Basal metabolic rate | Basal metabolic rate variance | ETC | Wang H | 2019 | NA | 341,584 | 1.00e-2 | 9.85e-3 |
Basal metabolic rate | Basal metabolic rate variance | ETC | Wang H | 2019 | NA | 341,584 | 1.00e-3 | 2.76e-4 |
Basal metabolic rate | Basal metabolic rate variance | ETC | Wang H | 2019 | NA | 341,584 | 1.00e-4 | 4.78e-5 |
Basal metabolic rate | Basal metabolic rate variance | ETC | Wang H | 2019 | NA | 341,584 | 1.00e-5 | 2.94e-2 |
BMI | Body mass index variance | ETC | Wang H | 2019 | NA | 346,393 | 1.00e-3 | 2.16e-2 |
BMI | Body mass index variance | ETC | Wang H | 2019 | NA | 346,393 | 1.00e-4 | 1.05e-2 |
BMI | Body mass index variance | ETC | Wang H | 2019 | NA | 346,393 | 1.00e-5 | 9.23e-4 |
Waist circumference | Waist circumference variance | ETC | Wang H | 2019 | NA | 347,158 | 5.00e-2 | 1.54e-2 |
Waist circumference | Waist circumference variance | ETC | Wang H | 2019 | NA | 347,158 | 1.00e-2 | 2.30e-4 |
Waist circumference | Waist circumference variance | ETC | Wang H | 2019 | NA | 347,158 | 1.00e-3 | 2.75e-3 |
Waist circumference | Waist circumference variance | ETC | Wang H | 2019 | NA | 347,158 | 1.00e-4 | 2.77e-3 |
Waist circumference | Waist circumference variance | ETC | Wang H | 2019 | NA | 347,158 | 1.00e-5 | 3.08e-4 |
Hip circumference | Hip circumference variance | ETC | Wang H | 2019 | NA | 346,781 | 1.00e-3 | 6.52e-3 |
Hip circumference | Hip circumference variance | ETC | Wang H | 2019 | NA | 346,781 | 1.00e-4 | 9.14e-4 |
Hip circumference | Hip circumference variance | ETC | Wang H | 2019 | NA | 346,781 | 1.00e-5 | 3.39e-4 |
Systemic sclerosis | Systemic sclerosis | ETC | Lopez-Isac E | 2019 | 9,095 | 17,584 | 5.00e-2 | 2.69e-2 |
Systemic sclerosis | Systemic sclerosis | ETC | Lopez-Isac E | 2019 | 9,095 | 17,584 | 1.00e-2 | 6.62e-4 |
Systemic sclerosis | Systemic sclerosis | ETC | Lopez-Isac E | 2019 | 9,095 | 17,584 | 1.00e-3 | 6.36e-3 |
Systemic sclerosis | Systemic sclerosis | ETC | Lopez-Isac E | 2019 | 9,095 | 17,584 | 1.00e-4 | 1.57e-2 |
Systemic sclerosis | Systemic sclerosis | ETC | Lopez-Isac E | 2019 | 9,095 | 17,584 | 1.00e-5 | 1.81e-2 |
Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis (MPO-ANCA positive) | ETC | Lyons PA | 2019 | 159 | 6,688 | 5.00e-2 | 4.63e-2 |
Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis (MPO-ANCA positive) | ETC | Lyons PA | 2019 | 159 | 6,688 | 1.00e-4 | 1.78e-2 |
Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis (MPO-ANCA positive) | ETC | Lyons PA | 2019 | 159 | 6,688 | 1.00e-5 | 3.98e-3 |
Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis (ANCA negative) | ETC | Lyons PA | 2019 | 352 | 6,688 | 1.00e-2 | 4.65e-3 |
Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis (ANCA negative) | ETC | Lyons PA | 2019 | 352 | 6,688 | 1.00e-3 | 2.96e-4 |
Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis | ETC | Lyons PA | 2019 | 534 | 6,688 | 5.00e-2 | 3.75e-2 |
Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis | ETC | Lyons PA | 2019 | 534 | 6,688 | 1.00e-2 | 3.81e-2 |
Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis | ETC | Lyons PA | 2019 | 534 | 6,688 | 1.00e-3 | 8.23e-3 |
Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis | ETC | Lyons PA | 2019 | 534 | 6,688 | 1.00e-4 | 9.48e-4 |
PD | Parkinson's disease in GBA mutation carriers | ETC | Blauwendraat C | 2020 | 1,588 | 7,584 | 1.00e-2 | 2.11e-2 |
Left ventricular | Left ventricular mass to end-diastolic volume ratio | ETC | Aung N | 2019 | NA | 16,884 | 5.00e-2 | 3.50e-2 |
Refractive error | Refractive error (autorefraction measured) | ETC | Ghorbani Mojarrad N | 2020 | NA | 95,619 | 1.00e-3 | 6.73e-3 |
Refractive error | Refractive error (autorefraction measured) | ETC | Ghorbani Mojarrad N | 2020 | NA | 95,619 | 1.00e-4 | 4.83e-2 |
IL 6 | Interleukin-6 receptor subunit alpha levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-4 | 7.94e-3 |
Albumin to creatinine ratio | Urinary albumin-to-creatinine ratio | ETC | Casanova F | 2019 | NA | 437,027 | 1.00e-2 | 3.60e-2 |
* If the number of cases is 0/NA, it means the phenotype is a continuous data type and the number of controls is the total number of samples.